The Japanese company of Technological Services Fujitsu has collaborated in the development of a mobile application that helps improve the treatment and monitoring of gestational diabetes.

The mobile application measures in real time the blood glucose levels, physical activity, nutrition and the daily weight of the mother in a project that has used an artificial intelligence system based on automatic learning so that the treatment is inLine with the patient's risk profile.

This system allows predictions on the future health of the mother and the child.

Fujitsu has been in charge, in particular, the integration and processing of the data, as well as the development of the user interface for medical care personnel;And he has worked in collaboration with Cleverhealth Network, an ecosystem coordinated by the Helsinki hospital (HUS), and Uusima, an authority formed by 24 Finnish municipalities that seeks to offer quality access to specialized medicine.

Cleverhealth Network, an ecosystem coordinated by HUS, Helsinki and Uusimaa hospital district, an authority formed by 24 municipalities whose objective is to offer specialized medicine access, is launching a development project to support the treatment of gestational diabetes.It is a new model of digital service based on artificial intelligence, in which Fujitsu is in charge of the integration and processing of the data, as well as the user interface for medical care personnel.

The project aims to improve the treatment and monitoring of gestational diabetes through the development of a mobile application to measure blood glucose levels, physical activity, nutrition, pulse and mother's daily weight in real time.

Fujitsu is in charge of the integration and processing of the data to make these compatible with the data of HUS and the Health Record personal organization (Kanta PHR).An environment in which citizens can store information about their health and well -being, according to their own measurements.Fujitsu will also design the user interface for medical care personnel.

The project uses automatic learning so that both orientation and treatment are in line with the patient's risk profile and meet their individual needs.Artificial intelligence also allows predictions on the future health of the mother and the child.

The development projects of Cleverhealth Network gather the excellent health technology skills of Finnish companies, leading experts in medical care and high quality health data collected by HUS.The main partners in the gestational diabetes project are Hus, Elisa, Fujitsu, the University of Aalto and Helsinki and is launched with financing granted by Business Finland.